Clinicopathological Characteristics and Prognostic Significance of Casting-type Calcifications in Patients with Invasive Breast Cancer Presenting with Microcalcification

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 10

PMID 38858542

Authors

Jiang Wang

Liangying Zhao

Xiaoshan Hu

Liting Lv

Xiaowei Zhang

Minjun Lu

Guinv Hu

Affiliations

Soon will be listed here.

Abstract

To explore the clinicopathological characteristics and prognostic significance of casting-type calcification (CC) in patients with breast cancer presenting with microcalcification on mammography. Data on patients with invasive breast cancer who had mammographic calcification was retrospectively analyzed. The chi-square test was utilized to assess the clinicopathological characteristics of two forms of CC-related breast cancer. The examination of prognostic variables was conducted using Kaplan-Meier and Cox regression analyses. A total of 427 eligible patients were included in this study. Chi-square analysis indicated that the presence of CC was associated with estrogen receptor (ER) negativity (P = 0.005), progesterone receptor (PR) negativity (P < 0.001), and epidermal growth factor receptor 2 (HER-2) positivity (P < 0.001); among these, the association was stronger with the CC-predominant type. After a median follow-up of 82 months, those with CC had a worse 5-year recurrence-free survival (RFS) (77.1% vs. 86.9%, p = 0.036; hazard ratio [HR], 1.86; 95% confidence interval [CI] 1.04-3.31) and overall survival (OS) (84.0% vs. 94.4%, p = 0.007; HR, 2.99; 95% CI 1.34-6.65) rates. In COX regression analysis, such differences were still observed in HER-2 positive subgroups (RFS: HR: 2.45, 95% CI 1-5.97, P = 0.049; OS: HR: 4.53, 95% CI 1.17-17.52, P = 0.029). In patients with invasive breast cancer exhibiting calcifications on mammography, the presence of CC, especially the CC-predominant type, is linked to a higher frequency of hormone receptor negativity and HER-2 positivity. The presence of CC is associated with an unfavorable 5-year RFS and OS rates.

References

Wolff A, Somerfield M, Dowsett M, Hammond M, Hayes D, McShane L . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023; 41(22):3867-3872. DOI: 10.1200/JCO.22.02864. View

Tabar L, Dean P, Lee Tucker F, Yen A, Fann J, Lin A . Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB. Eur J Radiol. 2022; 152:110323. DOI: 10.1016/j.ejrad.2022.110323. View

Allison K, Hammond M, Dowsett M, McKernin S, Carey L, Fitzgibbons P . Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020; 38(12):1346-1366. DOI: 10.1200/JCO.19.02309. View

Wu W, Tabar L, Tot T, Fann C, Yen A, Chen S . Imaging Biomarkers as Predictors for Breast Cancer Death. J Oncol. 2019; 2019:2087983. PMC: 6481030. DOI: 10.1155/2019/2087983. View

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

Zunzunegui R, Chung M, Oruwari J, Golding D, Marchant D, Cady B . Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease?. Arch Surg. 2003; 138(5):537-40. DOI: 10.1001/archsurg.138.5.537. View

Ling H, Liu Z, Xu L, Xu X, Liu G, Shao Z . Malignant calcification is an important unfavorable prognostic factor in primary invasive breast cancer. Asia Pac J Clin Oncol. 2012; 9(2):139-45. DOI: 10.1111/j.1743-7563.2012.01572.x. View

Rauch G, Hobbs B, Kuerer H, Scoggins M, Benveniste A, Park Y . Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Ann Surg Oncol. 2015; 23(2):482-9. PMC: 5040326. DOI: 10.1245/s10434-015-4876-6. View

Karamouzis M, Likaki-Karatza E, Ravazoula P, Badra F, Koukouras D, Tzorakoleftherakis E . Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer. 2002; 102(1):86-90. DOI: 10.1002/ijc.10654. View

10.

Tsau H, Yen A, Fann J, Wu W, Yu C, Chen S . Mammographic tumour appearance and triple-negative breast cancer associated with long-term prognosis of breast cancer death: a Swedish Cohort Study. Cancer Epidemiol. 2015; 39(2):200-8. DOI: 10.1016/j.canep.2015.01.013. View

11.

Tabar L, Dean P, Lee Tucker F, Yen A, Chen S, Jen G . A new approach to breast cancer terminology based on the anatomic site of tumour origin: The importance of radiologic imaging biomarkers. Eur J Radiol. 2022; 149:110189. DOI: 10.1016/j.ejrad.2022.110189. View

12.

GERSHON-COHEN J, Berger S . Breast cancer with microcalcifications: diagnostic difficulties. Radiology. 1966; 87(4):613-22. DOI: 10.1148/87.4.613. View

13.

Tot T, Gere M, Hofmeyer S, Bauer A, Pellas U . The clinical value of detecting microcalcifications on a mammogram. Semin Cancer Biol. 2019; 72:165-174. DOI: 10.1016/j.semcancer.2019.10.024. View

14.

Nair N, Sanchez Calle A, Zahra M, Prieto-Vila M, Oo A, Hurley L . A cancer stem cell model as the point of origin of cancer-associated fibroblasts in tumor microenvironment. Sci Rep. 2017; 7(1):6838. PMC: 5533745. DOI: 10.1038/s41598-017-07144-5. View

15.

Spak D, Plaxco J, Santiago L, Dryden M, Dogan B . BI-RADS fifth edition: A summary of changes. Diagn Interv Imaging. 2017; 98(3):179-190. DOI: 10.1016/j.diii.2017.01.001. View

16.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

17.

Tabar L, Dean P, Lee Tucker F, Chen T, Smith R, Duffy S . Imaging biomarkers of breast cancers originating from the major lactiferous ducts: Ductal adenocarcinoma of the breast, DAB. Eur J Radiol. 2022; 154:110394. DOI: 10.1016/j.ejrad.2022.110394. View

18.

Palka I, Ormandi K, Gaal S, Boda K, Kahan Z . Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients. Acta Oncol. 2007; 46(8):1178-83. DOI: 10.1080/02841860701373611. View

19.

Li Y, Cao J, Zhou Y, Mao F, Shen S, Sun Q . Mammographic casting-type calcification is an independent prognostic factor in invasive breast cancer. Sci Rep. 2019; 9(1):10544. PMC: 6646401. DOI: 10.1038/s41598-019-47118-3. View

20.

Tabar L, Dean P . Teaching atlas of mammography. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1983; 116:1-222. View